The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors

Thromb Haemost. 2004 Mar;91(3):425-37. doi: 10.1160/TH03-12-0764.

Abstract

Plasminogen activator inhibitor-I (PAI-I) is an important component of the plasminogen/plasmin system as it is the main inhibitor of tissue-type and urokinase-type plasminogen activator. Consequently, PAI-I plays an important role in cardiovascular diseases (mainly through inhibition of t-PA), and in cell migration and tumor development (mainly through inhibition of u-PA and interaction with vitronectin). As a member of the serpin superfamily, PAI-I shares important structural properties with other serpins. However, PAI-I also exhibits unique conformational and functional properties. The current review provides an overview of the knowledge on PAI-I gathered since its discovery two decades ago. We discuss (a) its structural properties of the protein and their subsequent relation to functional activities, (b) its role in a wide variety of (patho)physiological processes and (c) a number of strategies to interfere with its functional properties eventually aiming at pharmacological modulation of this risk factor.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / chemistry
  • Binding Sites
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / physiopathology*
  • Cell Movement
  • Fibrinolysis / drug effects
  • Humans
  • Models, Chemical
  • Models, Molecular
  • Neoplasms / pathology
  • Peptides / chemistry
  • Plasminogen Activator Inhibitor 1 / physiology*
  • Plasminogen Inactivators / therapeutic use*
  • Protein Binding
  • Protein Conformation
  • Protein Structure, Secondary
  • Recombinant Proteins / chemistry

Substances

  • Antibodies, Monoclonal
  • Peptides
  • Plasminogen Activator Inhibitor 1
  • Plasminogen Inactivators
  • Recombinant Proteins